#United States #Sheridan #IVD Quality Control #Wissen Research #Automated QC

IVD Quality Control Market Insights: A Growth Surge Ahead

The global market for In Vitro Diagnostic (IVD) quality control is poised for significant expansion, expected to rise from USD 1.7 billion in 2026 to USD 2.2 billion by 2031. This growth trajectory predicts a CAGR of 5.3% during the forecast period from 2026 through 2031, according to insights revealed in a recent report by Wissen Research.

Key Drivers of Market Growth

The primary catalysts behind this upward trend include:
1. Increasing Testing Volumes: Laboratories are witnessing a surge in testing demands linked to clinical chemistry, immunoassay, and molecular diagnostics. The complexity of tests is raising the bar for quality assurance practices.
2. Regulatory Compliance: With stringent frameworks, such as CLIA, requiring meticulous documentation of quality control protocols, the adoption of internal QC measures and proficiency testing is accelerating.
3. Shift Toward Automation: As laboratories embrace automation, there's a growing need for digital quality control monitoring, statistical analysis, and automated evaluation of rules.
4. Point-of-Care Testing: The expansion of decentralized testing is generating a demand for QC products that simplify performance verification outside of traditional lab settings.
5. Standardization in Laboratories: A heightened focus on standardizing laboratory processes is promoting the use of third-party control reagents and external quality assessments.

The Evolution of Laboratory Quality Control

Recent advancements indicate a significant paradigm shift in laboratory QC. Traditionally, quality control has been a manual task, often conducted as a standalone operation. However, the trend is moving towards integrating automated processes directly into daily testing workflows. A leader in this evolution, Roche's navify Lab Operations, offers integrated QC management tools aimed to facilitate this transition. They provide features such as configurable QC rules and real-time alerts for quality issues.

One key innovation is the introduction of real-time patient-based quality monitoring, allowing labs to track analyzer performance actively and receive early warning signs of potential issues. Additionally, risk-based approaches to QC, such as the CDC's Individualized Quality Control Plan (IQCP), empower laboratories to tailor QC practices aligning with their unique environments rather than adhering to generic methods.

Challenges in the IVD Quality Control Market

While the prospects look bright, there are notable challenges impacting the IVD quality control market:

• - Standardization Issues: Laboratories utilizing various analyzers and assay types face hurdles in standardizing QC protocols, which complicates performance evaluations across platforms.
• - Implementation Costs: Smaller laboratories or decentralized testing sites must navigate the financial burdens that come with adopting sophisticated QC materials and digital systems, in addition to necessary training and data management.
• - Holistic Quality Assurance: It's crucial to recognize that QC is just one component of a broader quality management framework comprising staff training, adherence to standard operating procedures, and proficiency evaluations.

Notable Developments in the Market

Several strategic moves in the market have indicated a proactive approach towards enhancing quality control solutions:

• - In May 2026, RealBio collaborated with Thermo Fisher Scientific, pooling expertise in IVD solutions to bolster local regulatory frameworks and raw material development.
• - Siemens Healthineers marked a milestone in July 2025 by becoming the first manufacturer to receive the My Green Lab ACT Ecolabel for its Atellica analyzers, emphasizing sustainability in their product line.

These developments reflect a critical emphasis on marrying global standards with local regulatory knowledge, illustrating an industry keen on sustainable and efficient QC solutions.

Key Market Segments and Players

In 2025, immunoassay/immunochemistry technologies dominated market share, attributed to their prevalent automation in testing processes across various health parameters. The hospital segment led end-user engagement driven by diverse clinical testing needs, and North America emerged as the leading market region, supported by robust lab infrastructures and stringent compliance requirements.

Prominent players shaping the IVD quality control landscape include:

• - Abbott Laboratories: Offering robust QC materials for automated systems.
• - Roche Diagnostics: Focused on integrated QC management solutions.
• - Siemens Healthineers AG: Known for sustainability in QC reagents.
• - Thermo Fisher Scientific: A leader in QC reagents across diagnostics.

As the industry adapts and evolves, the growth narrative underscores an ongoing integration of quality control into daily laboratory operations instead of viewing it as mere compliance. Companies looking to maintain a competitive edge must invest in emerging digital QC platforms and develop solutions tailored to decentralized testing locations.

Conclusion

With continuing advancements in automated technologies and quality oversight practices, the IVD quality control market is set for a transformative future. Stakeholders must remain vigilant, prioritizing innovation and responsiveness to emerging challenges while ensuring rigorous quality management practices to uphold patient safety and diagnostic accuracy.

For those interested in tailored market insights, Wissen Research's healthcare technology analysts are available to provide personalized information tailored to specific market dynamics.